Send to printer »

GEN News Highlights : Feb 20, 2007

Pro-Pharmaceuticals Works with Chemwerth to Scale Up Davanat

Firms target 100 kilos per batch.

Pro-Pharmaceuticals is collaborating with Chemwerth to scale up production of its lead drug candidate, DavanatĀ®, to 100 kilograms for initial marketing needs. 

Davant is a carbohydrate polymer composed of mannose and galactose (galactomannan). Pro-Pharmaceuticals believes  that its mechanism of action is based upon binding to lectins on the cell surface. It thus theorizes that the product targets specific lectin receptors that are over-expressed on cancer cells.

Current research indicates that Galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis, and tumor metastasis, according to a Pro-Pharmaceuticals. The company hence believes that this form of targeted delivery may allow for higher doses of chemotherapy administration with no increase in toxicity.